

Regimen Reference Order – ENDO – selpercatinib

ARIA: ENDO - [selpercatinib (under 50kg)]

ENDO - [selpercatinib (50kg or more)]

Planned Course: Twice daily until disease progression or unacceptable toxicity (1 cycle = 30 days)

Indication for Use: Thyroid Cancer, RET Fusion-Positive

Proceed with treatment if:

- ***ANC equal to or greater than $1 \times 10^9/L$ AND Platelets equal to or greater than $75 \times 10^9/L$***
- ***AST/ALT less than 5 times upper limit of normal***
- ***Total bilirubin less than 3 times upper limit of normal***
- ❖ **Contact Physician if parameters not met**

SEQUENCE OF MEDICATION ADMINISTRATION

Treatment Regimen – ENDO – selpercatinib

Drug	Dose	CCMB Administration Guideline
selpercatinib	<u>Body weight less than 50 kg:</u> 120 mg	Orally twice daily with or without food Swallow whole (Self-administered at home)
	<u>Body weight greater than or equal to 50 kg:</u> 160 mg	
selpercatinib (RETEVMO®) available dosage strengths: 40 mg and 80 mg capsules Classification: Cytotoxic, Hazardous		

REQUIRED MONITORING

Cardiac Monitoring

- Blood Pressure
 - At baseline, then
 - 1 week after starting selpercatinib, then
 - every month as per Physician Orders
- EKG
 - At baseline, then
 - 1 week after starting selpercatinib, then
 - every month for 6 months, then
 - every 3 to 4 months as clinically indicated as per Physician Orders

Cycle 1

Day 1

- CBC, serum creatinine, urea, electrolytes (including potassium, calcium and magnesium), liver enzymes, total bilirubin, glucose and albumin as per Physician Orders
- TSH prior to Cycle 1 then every 3 cycles thereafter as per Physician Orders

Days 8 and 15

- Electrolytes (including potassium, calcium and magnesium), liver enzymes, and albumin as per Physician Orders

Cycles 2 and 3

Day 1

- CBC, serum creatinine, urea, electrolytes (including potassium, calcium and magnesium), liver enzymes, total bilirubin, glucose and albumin as per Physician Orders

Day 15

- Liver enzymes

Cycle 4 and Onwards

Day 1

- CBC, serum creatinine, urea, electrolytes (including potassium, calcium and magnesium), liver enzymes, total bilirubin, glucose and albumin as per Physician Orders
- TSH every 3 cycles as per Physician Orders

Recommended Support Medications

Drug	Dose	CCMB Administration Guideline
None required		

INSTRUCTIONS FOR PATIENT

- Patients should be instructed to contact their cancer team immediately if symptoms of hypersensitivity reactions occur
- selpercatinib has potential for drug-drug interactions. Patients should notify clinic prior to starting any new medication
- Avoid grapefruit and grapefruit juice, Seville oranges (i.e. orange marmalade) and starfruit
- Acid-reducing agents should be avoided while on selpercatinib. If concomitant use cannot be avoided:
 - selpercatinib should be taken with food if patient is taking a proton pump inhibitor (e.g. omeprazole, pantoprazole, esomeprazole, lansoprazole)
 - selpercatinib should be taken 2 hours before or 10 hours after an H₂-receptor antagonist (e.g. ranitidine, famotidine)
 - selpercatinib should be taken 2 hours before or 2 hours after a locally acting antacid (e.g. calcium carbonate, aluminum hydroxide, magnesium hydroxide, simethicone)
- Reinforce applicable safe handling precautions of medications, blood and body fluids while on selpercatinib

ADDITIONAL INFORMATION

- selpercatinib can cause QT prolongation
- selpercatinib has been associated with hypersensitivity that can present as fever, rash, myalgia/arthralgia, with concurrent decreased platelets or AST/ALT increase
- selpercatinib can cause hypertension, hepatotoxicity, hemorrhage and impaired wound healing
- selpercatinib will be dispensed by CCMB Pharmacy